At a glance
- Originator Novartis
- Class
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia